Cereseto A, Mulloy J C, Franchini G
Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4255, USA.
J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S69-75. doi: 10.1097/00042560-199600001-00013.
Human T-lymphotropic/leukemia virus types I and II (HTLV-I and HTLV-II) are phylogenetically and immunologically related viruses that differ in their pathogenicity in vivo. HTLV-I is the etiologic agent of adult T-cell leukemia/lymphoma, as well as a chronic progressive myelopathy, HTLV-I-associated myelopathy/tropical spastic paraparesis. In contrast, HTLV-II has not been conclusively associated with specific diseases. Both HTLV-I and HTLV-II transform CD4+ T-cells in vitro, but their in vivo target cells appear to differ. HTLV-I is found mainly in CD4+ cells, whereas HTLV-II has been demonstrated mainly in CD8+ cells. Clearly the definition of the viral genetic determinants responsible for the different tropism and pathogenicity in vivo may provide the basis of our understanding of the HTLV-I oncogenicity. In this short review we emphasize two aspects of viral infection of T cells: (1) the influence of viral infection on the major proteins involved in the G0-G1 phase of the cell cycle and (2) the effect of viral infection on the S phase of the cell cycle, i.e., the interleukin-2 receptor pathway.
人类嗜T淋巴细胞病毒I型和II型（HTLV-I和HTLV-II）在系统发育和免疫方面相关，但其体内致病性有所不同。HTLV-I是成人T细胞白血病/淋巴瘤以及慢性进行性脊髓病（HTLV-I相关脊髓病/热带痉挛性截瘫）的病原体。相比之下，HTLV-II尚未与特定疾病明确相关。HTLV-I和HTLV-II在体外均可转化CD4+ T细胞，但它们在体内的靶细胞似乎不同。HTLV-I主要存在于CD4+细胞中，而HTLV-II主要存在于CD8+细胞中。显然，确定负责体内不同嗜性和致病性的病毒遗传决定因素，可能为我们理解HTLV-I的致癌性提供基础。在这篇简短的综述中，我们强调T细胞病毒感染的两个方面：（1）病毒感染对细胞周期G0-G1期主要蛋白质的影响，以及（2）病毒感染对细胞周期S期的影响，即白细胞介素-2受体途径。
